On May 29, the NMPA official website shows that FOSUNPHARMA/Helsinn’s Class 5.1 imported new drug, AKYNZEO® concentrated solution for injection, obtains marketing approval in China for the prevention of chemotherapy‑induced nausea and vomiting. AKYNZEO® intravenous injection (NEPA) is a fixed‑dose…
RAS is one of the most frequently mutated genes in human cancers. As an important member of the small GTPase family, RAS proteins act as “molecular switches,” cycling between the GTP-bound “ON” active state and the GDP-bound “OFF” inactive state.…
Anbenitamab injection (KN026) is an anti-HER2 bispecific antibody independently developed by the Company using the proprietary Fc-based heterodimer bispecific platform technology called CRIB (Charge Repulsion Induced Bispecific). Anbenitamab can simultaneously bind two non-overlapping epitopes of HER2, resulting in HER2 signal blockade.…
On May 28, the NMPA website announced that Hengrui Pharma’s Class 1 new drug SHR4640 has been approved for marketing in patients with gout and hyperuricemia. SHR4640 (R&D code: SHR4640; also known as Ruzinurad) is a highly selective small-molecule inhibitor…
On May 28, the NMPA website shows that Beijing Northland Biotechnology’s Class 1 new drug **NL003** is approved for market in China for the treatment of ulcers caused by critical limb ischemia (CLI). NL003 injection is a novel plasmid-based gene…
Currently, Class 1.1 innovative TCM drugs for bronchial asthma chronic persistent phase (Cold Wheezing Syndrome) remain scarce.YRPG’s ZGZHR-061 Granules target this condition, fitting respiratory chronic disease needs. The drug first filed for a clinical trial on March 13, 2026, and…
On May 21, the NMPA website announced that Johnson & Johnson’s innovative drug with a novel mechanism,Nipocalimab Injection (trade name:IMAAVY®), officially received marketing approval from the National Medical Products Administration (NMPA). It can be used in combination with conventional treatment…
On May 21, the NMPA website announced that Yangtze River Pharmaceutical Group (YRPG)’s Class 1 new drug Fazamorexant Tablets had been approved for marketing in China for the treatment of insomnia. This is the first domestic dual orexin receptor antagonist approved in…
Dorner® is the commercial brand name of Beraprost sodium, an orally active prostacyclin (PGI2) analogue developed by Toray Industries of Japan. It acts on prostacyclin receptors on blood vessels and platelets to dilate blood vessels and inhibit platelet aggregation, thus…
Onradivir granules (generic name: Onradivir, research code: ZSP1273) are a Class 1 chemical innovative drug independently developed by Raynovent in Guangdong, China, and represent the world’s first pediatric formulation of an influenza A virus RNA polymerase PB2 inhibitor. On May 22,…